0001209191-18-056332.txt : 20181026
0001209191-18-056332.hdr.sgml : 20181026
20181026184358
ACCESSION NUMBER: 0001209191-18-056332
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20181024
FILED AS OF DATE: 20181026
DATE AS OF CHANGE: 20181026
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Mahatme Sandesh
CENTRAL INDEX KEY: 0001511034
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-14895
FILM NUMBER: 181142561
MAIL ADDRESS:
STREET 1: C/O CELGENE CORPORATION
STREET 2: 86 MORRIS AVENUE
CITY: SUMMIT
STATE: NJ
ZIP: 07901
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Sarepta Therapeutics, Inc.
CENTRAL INDEX KEY: 0000873303
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 930797222
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 215 FIRST STREET
STREET 2: SUITE 415
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 617-274-4000
MAIL ADDRESS:
STREET 1: 215 FIRST STREET
STREET 2: SUITE 415
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
FORMER COMPANY:
FORMER CONFORMED NAME: Sarepta Therapuetics, Inc.
DATE OF NAME CHANGE: 20120712
FORMER COMPANY:
FORMER CONFORMED NAME: AVI BIOPHARMA INC
DATE OF NAME CHANGE: 19980930
FORMER COMPANY:
FORMER CONFORMED NAME: ANTIVIRALS INC
DATE OF NAME CHANGE: 19970123
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2018-10-24
0
0000873303
Sarepta Therapeutics, Inc.
SRPT
0001511034
Mahatme Sandesh
215 FIRST STREET, SUITE 415
CAMBRIDGE
MA
02142
0
1
0
0
EVP, CFO & CBO
Common Stock
2018-10-24
4
M
0
9596
23.85
A
48381
D
Common Stock
2018-10-24
4
M
0
39006
13.90
A
87387
D
Common Stock
2018-10-24
4
M
0
29080
13.71
A
116467
D
Common Stock
2018-10-24
4
M
0
11718
13.71
A
128185
D
Common Stock
2018-10-24
4
S
0
107524
127.74
D
20661
D
Common Stock
2018-10-24
5
G
0
E
12012
0.00
D
8649
D
Common Stock
2018-10-24
5
G
0
E
12012
0.00
A
12012
I
By wife
Stock Option (right to buy)
23.85
2018-10-24
4
M
0
9596
0.00
D
2022-11-05
Common Stock
9596
116009
D
Stock Option (right to buy)
13.90
2018-10-24
4
M
0
39006
0.00
D
2025-02-27
Common Stock
39006
17860
D
Stock Option (right to buy)
13.71
2018-10-24
4
M
0
29080
0.00
D
2026-02-28
Common Stock
29080
7899
D
Stock Option (right to buy)
13.71
2018-10-24
4
M
0
11718
0.00
D
2026-02-28
Common Stock
11718
12873
D
These trades were made pursuant to a Rule 10b5-1 trading plan.
The shares were sold in multiple transactions at prices ranging from $120.87 to $134.39, inclusive. The reporting person undertakes to provide to Sarepta Therapeutics, Inc., any security holder of Sarepta Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price with the range set forth herein.
This transaction involved a gift of securities by the reporting person to his wife.
The option to purchase shares is fully vested.
The option vests based on time criteria (25% of the total option on 2/27/2016 and 1/48th of the total option in equal monthly installments thereafter).
Half of the total options granted began vesting when the FDA provided marketing approval for eteplirsen on 9/19/2016 and the other half of the total options granted began vesting when Sarepta Therapeutics, Inc. filed a Marketing Authorization Application with the European Medicines Agency on 11/30/2016. Vesting of the options allocated to the achievement of each goal is as follows: (i) 50% of the options allocated to the achieved goal vested immediately upon achievement of the performance condition (25% of the total performance-based options granted) and (ii) the remaining 50% of the options allocated to the achieved goal (25% of the total performance-based options granted) vest over four years. 25% of the remaining options vested on the first year anniversary of the grant date, or 2/28/2017 and 1/48th of the remaining options vests monthly thereafter.
The option vests based on time criteria (25% of the total option on 2/29/2017 and 1/48th of the total option in equal monthly installments thereafter).
/s/ David Tyronne Howton, as attorney-in-fact for Sandesh Mahatme
2018-10-26